Volume 23, Issue 3 (Iranian South Medical Journal 2020)                   Iran South Med J 2020, 23(3): 248-256 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Abbaszadeh M, Tangestani A, Jokar N, Ravanbod M, KalantarHormozi M. Prognostic Factors in the Survival Rate of Patients with Differentiated Thyroid Cancer. Iran South Med J 2020; 23 (3) :248-256
URL: http://ismj.bpums.ac.ir/article-1-1307-en.html
1- Department of Internal Medicine, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
2- The Persian Gulf Nuclear Medicine Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
3- Department of Internal Medicine, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran , m.kalantarhormozi@yahoo.com
Abstract:   (3342 Views)
Background: Thyroid cancer is the most prevalent malignancy of the endocrine systemcancers. Thyroid cancer has increased faster thatn any other malignancy in recent years. Tyroid cancer has different histopathologic types, of which the most common is the differentiated type. Different factors can affect the prognosis of the patients. In this study, we investigated different factors that can affect the prognosis of these patients.
Materials and Methods: Thirty-four patients underwent the standard surgery including partial and total thyroidectomy and subsequently received 131I radioiodine 4-6 weeks after surgery. We evaluated the effects of different prognostic factors which can effect on the patients’ survival including age, gender, family history of any malignancies, history of radiation exposure, histopathological type and lab data on the ablation time including serum Tg, serum Anti Tg and thyroid-stimulating hormone (TSH) levels.
Results: A total of 34 patients, including 6 males (17.6%) and 28 (82.4%) females with a mean age of 40.8±11.6 years participated in this research. Only vascular invasion had statistically significant P-values less than 0.05, which shows the correlation between ablation success and this factor.
Conclusion: This study demonstrated that among different prognostic factors, only vascular invasion had a reverse relationship with ablation success. Other factors did not show statistically significant relashionships with treatment efficiency of DTC.
Full-Text [PDF 765 kb]   (1942 Downloads)    
Type of Study: Original | Subject: Endocrine System
Received: 2020/01/4 | Accepted: 2020/05/30 | Published: 2020/07/27

1. Fitzmaurice C, Dicker D, Pain A, et al. The Global Burden Of Cancer 2013. JAMA Oncol 2015; 1(4): 505-27. [DOI:10.1001/jamaoncol.2015.0735]
2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer Incidence And Mortality Worldwide: Sources, Methods And Major Patter ns In GLOBOCAN 2012. Int J Cancer 2015; 136(5): 359-86. [DOI:10.1002/ijc.29210]
3. Haddad RI, Lydiatt WM, Ball DW, et al. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015; 13(9): 1140-1150. [DOI:10.6004/jnccn.2015.0139]
4. Delellis RA. Pathology And Genetics Of Tumours Of Endocrine Organs, In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, editors. 3rd ed. Geneva: World Health Organization, 2004.
5. Mazzaferri EL. An Overview Of The Management Of Papillary And Follicular Thyroid Carcinoma. Thyroid 1999; 9(5): 421-7. [DOI:10.1089/thy.1999.9.421]
6. Segal K, Raveh E, Lubin E, et al. Well-Differentiated Thyroid Carcinoma. Am J Otolaryngol 1996; 17(6): 401-6. [DOI:10.1016/S0196-0709(96)90074-5]
7. Simpson WJ, Mckinney SE, Carruthers JS, et al. Papillary And Follicular Thyroid Cancer: Prognostic Factors In 1,578 Patients. Am J Med 1987; 83(3): 479-88. [DOI:10.1016/0002-9343(87)90758-3]
8. Shah JP, Loree TR, Dharker D, et al. Prognostic Factors In Differentiated Carcinoma Of The Thyroid Gland. Am J Surg 1992; 164(6): 658-61. [DOI:10.1016/S0002-9610(05)80729-9]
9. Passler C, Scheuba C, Prager G, et al. Prognostic Factors Of Papillary And Follicular Thyroid Cancer: Differences In An Iodine-Replete Endemic Goiter Region. Endocr Relat Cancer 2004; 11(1): 131-9. [DOI:10.1677/erc.0.0110131]
10. Lerch H, Schober O, Kuwert T, et al. Survival Of Differentiated Thyroid Carcinoma Studied In 500 Patients. J Clin Oncol 1997; 15(5): 2067-75. [DOI:10.1200/JCO.1997.15.5.2067]
11. Cady B. Presidential Address: Beyond Risk Groups--A New Look At Differentiated Thyroid Cancer. Surgery 1998; 124(6): 947-57. [DOI:10.1016/S0039-6060(98)70034-0]
12. Ito Y, Miyauchi A, Ito M, et al. Prognosis And Prognostic Factors Of Differentiated Thyroid Carcinoma After The Appearance Of Metastasis Refractory To Radioactive Iodine Therapy. Endocr J 2014; 61(8): 821-4. [DOI:10.1507/endocrj.EJ14-0181]
13. Chow SM, Law SC, Mendenhall WM, et al. Papillary Thyroid Carcinoma: Prognostic Factors And The Role Of Radioiodine And External Radiotherapy. Int J Radiat Oncol Biol Phys 2002; 52(3): 784-95. [DOI:10.1016/S0360-3016(01)02686-4]
14. Chow SM, Law SC, Mendenhall WM, et al. Follicular Thyroid Carcinoma: Prognostic Factors And The Role Of Radioiodine. Cancer 2002; 95(3): 488-98. [DOI:10.1002/cncr.10683]
15. Bellantone R, Lombardi CP, Boscherini M, et al. Prognostic Factors In Differentiated Thyroid Carcinoma: A Multivariate Analysis Of 234 Consecutive Patients. J Surg Oncol 1998; 68(4): 237-41. https://doi.org/10.1002/(SICI)1096-9098(199808)68:4<237::AID-JSO6>3.0.CO;2-5 [DOI:10.1002/(SICI)1096-9098(199808)68:43.0.CO;2-5]
16. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic Factors For Thyroid Carcinoma: A Population‐Based Study Of 15,698 Cases From The Surveillance, Epidemiology And End Results (SEER) Program 1973-1991. Cancer 1997; 79(3): 564-73. https://doi.org/10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0 [DOI:10.1002/(SICI)1097-0142(19970201)79:33.0.CO;2-0]
17. Shaha AR, Shah JP, Loree TR. Risk Group Stratification And Prognostic Factors In Papillary Carcinoma Of Thyroid. Ann Surg Oncol 1996; 3(6): 534-8. [DOI:10.1007/BF02306085]
18. Loh KC, Greenspan FS, Gee L, et al. Pathological Tumor-Node-Metastasis (Ptnm) Staging For Papillary And Follicular Thyroid Carcinomas: A Retrospective Analysis Of 700 Patients. J Clin Endocrinol Metab 1997; 82(11): 3553-62. [DOI:10.1210/jcem.82.11.4373]
19. Shaha AR, Loree TR, Shah JP. Intermediate-Risk Group For Differentiated Carcinoma Of Thyroid. Surgery 1994; 116(6): 1036-41.
20. Cady B, Rossi R. An Expanded View Of Risk-Group Definition In Differentiated Thyroid Carcinoma. Surgery 1988; 104(6): 947-53. [DOI:10.1016/S0039-6060(98)70034-0]
21. Carcangiu ML, Zampi V, Pupi A, et al. Papillary Carcinoma Of The Thyroid. A Clinicopathologic Study Of 241 Cases Treated At The University Of Florence, Italy. Cancer 1985; 55(4): 805-28. https://doi.org/10.1002/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO;2-Z [DOI:10.1002/1097-0142(19850215)55:43.0.CO;2-Z]
22. Yamashita H, Noguchi S, Murakami N, et al. Extracapsular Invasion Of Lymph Node Metastasis Is An Indicator Of Distant Metastasis And Poor Prognosis In Patients With Thyroid Papillary Carcinoma. Cancer 1997; 80(12): 2268-72. https://doi.org/10.1002/(SICI)1097-0142(19971215)80:12<2268::AID-CNCR8>3.0.CO;2-Q [DOI:10.1002/(SICI)1097-0142(19971215)80:123.0.CO;2-Q]
23. Krajewska J, Jarząb M, Czarniecka A, et al. Ongoing Risk Stratification For Differentiated Thyroid Cancer (DTC)-Stimulated Serum Thyroglobulin (Tg) Before Radioiodine (RAI) Ablation, The Most Potent Risk Factor Of Cancer Recurrence In M0 Patients. Endokrynol Pol 2016; 67(1): 2-11. [DOI:10.5603/EP.2016.0001]
24. Verburg FA, Keizer BD, Lips CJ, et al. Prognostic Significance Of Successful Ablation With Radioiodine Of Differentiated Thyroid Cancer Patients. Eur J Endocrinol 2005; 152(1): 33-7. [DOI:10.1530/eje.1.01819]

Send email to the article author

Rights and Permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian South Medical Journal

Designed & Developed by: Yektaweb